chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a nurse practitioner via company representative refers to a 72 year old male patient. The patient's medical history was not reported. On an unknown date the patient was vaccinated with ZOSTAVAX (route and dose was not reported). Concomitant medications were not reported. On an unknown date, the patient experienced severe case of shingles, after receiving ZOSTAVAX. Sought medical attention. Office visit on an unspecified date. At the time of report outcome of severe case of shingles, after receiving ZOSTAVAX was unknown. The relatedness of the event with the therapy of ZOSTAVAX was not provided. Additional information has been requested.
pt states that she started having pain in left back shoulder area and right upper thigh also left thumb was achy.  She also had a 98.8 fever that went up 99.0.  36 hours after vax pt had brain fog and she did not know where she was.  Pt has not contacted her PCP w/ her symptoms at this time.
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 40-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Aug-2021 at 9:28 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 26-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 26-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.   This case was linked to MOD-2021-405465, MOD-2021-405476, MOD-2021-405484, MOD-2021-405489, MOD-2021-405498, MOD-2021-405503, MOD-2021-405517, MOD-2021-405535, MOD-2021-405538, MOD-2021-405541, MOD-2021-405544, MOD-2021-405545, MOD-2021-405550, MOD-2021-405551, MOD-2021-405568, MOD-2021-405575, MOD-2021-405579, MOD-2021-405585, MOD-2021-405588, MOD-2021-405590, MOD-2021-405600, MOD-2021-405608, MOD-2021-405611, MOD-2021-405613, MOD-2021-405622, MOD-2021-405633, MOD-2021-405636, MOD-2021-405642, MOD-2021-405645, MOD-2021-405652, MOD-2021-405653, MOD-2021-405656, MOD-2021-405659, MOD-2021-405660, MOD-2021-405661, MOD-2021-405675, MOD-2021-405676, MOD-2021-405678, MOD-2021-405682, MOD-2021-405685, MOD-2021-405691, MOD-2021-405695, MOD-2021-405696, MOD-2021-405699, MOD-2021-405701, MOD-2021-405702, MOD-2021-405705, MOD-2021-405711, MOD-2021-405721, MOD-2021-405723, MOD-2021-405735, MOD-2021-405738, MOD-2021-405740, MOD-2021-405743, MOD-2021-405749, MOD-2021-405751, MOD-2021-405756, MOD-2021-405758, MOD-2021-405760, MOD-2021-405761, MOD-2021-405766, MOD-2021-405770, MOD-2021-405775, MOD-2021-405780, MOD-2021-405785, MOD-2021-405789, MOD-2021-405790, MOD-2021-405793, MOD-2021-405797, MOD-2021-405804, MOD-2021-405810, MOD-2021-405837, MOD-2021-405840, MOD-2021-405843, MOD-2021-405846, MOD-2021-405847, MOD-2021-405851, MOD-2021-405852, MOD-2021-405854, MOD-2021-405855, MOD-2021-405856, MOD-2021-405858, MOD-2021-405860, MOD-2021-405862, MOD-2021-405864, MOD-2021-405865, MOD-2021-405867, MOD-2021-405868, MOD-2021-405869, MOD-2021-405874, MOD-2021-405875, MOD-2021-405877, MOD-2021-405880, MOD-2021-405881, MOD-2021-405882, MOD-2021-405896, MOD-2021-405897, MOD-2021-405898, MOD-2021-405899, MOD-2021-405900, MOD-2021-405901, MOD-2021-405903, MOD-2021-405904 (Patient Link).
COVID BREAKTHROUGH CASE I had allergy symptoms went to work and had a PCR test Monday 16 May. I did a video appointment on the 18th and the followed their guidelines. My employer told me to isolate and dr instruction monitor symptoms since they were so minor. Dr decided that we were outside of the 5 day period so we decided not to take the Paxlovid.
may have received second dose of PNEUMOVAX 23 one month after receiving first dose of PNEUMOVAX 23; No adverse effects reported; Information has been received from a nurse referring to a patient of unknown age and gender. The patient's current conditions, concomitant medication and medical history were not reported.  On an unknown date, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (dose, route, lot number and expiration date were not reported) for prophylaxis. On an unknown date, the nurse reported that the patient might have received second dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) one month after receiving first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (Extra dose administered). No adverse effects reported. The outcome of the events was unknown.
Information has been received from a nurse practitioner referring to a patient of unknown age and gender. The patient's concomitant and historical conditions were not reported. On 04-JUN-2015, the patient was vaccinated with one dose of improperly stored (Oka/Merck) VARIVAX (dose, route, and site of administration were not reported, lot # K008819, expiration date 19-JUN-2016. No adverse symptoms were provided. This is one of several reports from the same reporter. Additional information has been requested.
Second dose not given in allowed time window; This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose not given in allowed time window) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose not given in allowed time window). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose not given in allowed time window) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant and treatment medications were not provided.
had shots 8MAR95 & 10MAR95 ran low grade fever 101; on 11MAR95 fever to 104 w/vomiting; temp WNL p/day 4;
Pt reports patch-like rashes on the arms, legs and neck, runny nose, headache, cough, stomach pain, left-side chest pain described as a feeling of uncomfortable indigestion as if the food or liquids are stuck, increased heart rate, and sore arm. The symptoms peaked one day (10/13/2023 in the afternoon) after receiving the Influenza, quadrivalent, adjuvanted [FLUAD Quadrivalent] vaccine. On Sunday, 10/15/2023 at around 9:30pm, pt reports experiencing left-sided pain feeling as if she is going to have a heart attack.
Prescriber ordered "DTaP" vaccination for this patient when "Tdap" is what should have been order.  The nurse administered the "DTaP" as was ordered by the physician.
Patient has reported no symptoms; Received unspecified dose in VAQTA series that was improperly stored; Expired vaccine used; This spontaneous report was received from a medical assistant refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions, historical drugs, drug reactions/allergies and concomitant medications were not reported. On 29-OCT-2019, the patient was vaccinated with unspecified dose in hepatitis a vaccine, inactivated (VAQTA) series, lot # S009562 and expiration date was reported as 26-JUL-2020, but upon internal validation established as 05-MAY-2019 (expired product administered) (strength, dose, route and anatomical location not reported) for prophylaxis that was improperly stored (product storage error). The storage temperature was reported as 48 Fahrenheit (F) for the time frame of 30 minutes. Previous temperature excursion included 50.4 F and 47.3 F for 30 minutes. Digital data logger involved. The patient had reported no symptoms (no adverse event). No product quality complaint (PQC) present.
Has still not gotten the second dose; passed out; fell; got a node on the head; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF CONSCIOUSNESS (passed out) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-May-2021, the patient experienced LOSS OF CONSCIOUSNESS (passed out) (seriousness criterion medically significant), FALL (fell) and HEAD DISCOMFORT (got a node on the head). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Has still not gotten the second dose). At the time of the report, LOSS OF CONSCIOUSNESS (passed out), FALL (fell) and HEAD DISCOMFORT (got a node on the head) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (Has still not gotten the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported.   Earlier, the physician had recommended the patient's mother to wait and hold with the second dose vaccination, probably due to the effects after first dose vaccination and so the patient decided not to get the second dose. The patient wanted to get the second dose now but was unsure whether the patient could receive it or not and if then had to restart the vaccination schedule or just get the second dose.  No treatment information was provided.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
pt began to feel hot, flushed & itchy about 30min p/vax no swelling or extreme redness noted @ inj site;
Information has been received from a nurse referring to a 68 year old female patient. The patient had no drug reactions/allergies. On 17-OCT-2016 the patient was vaccinated with a dose of PNEUMOVAX 23 (lot # M005287, expiration date: 08-OCT-2017, intramuscular). The patient was also administered an influenza virus vaccine in the same visit. At an unspecified time after the injection on 17-OCT-2016, the patient experienced pain in her arm that lasted for an unspecified amount of time. The nurse also reported that the patient vomited after she got out of the shower on the same day after administration. No treatment was given for the events and no lab diagnostic studies were performed. The current status of the patient was unknown at the time of the report. The causality was not reported. Additional information has been requested.
5yr old male received 3 vaccines DTaP, IPV, MMR on 4/18/06. Mom noted redness, swelling of left mid thigh to knee that evening. Child seen by Dr on 4/19/06 with DX of local reaction vs cellulitis RX Keflex x 10 days. No fever, minimal tenderness, warmth to touch.
Patient is complaining of numbness in the injected arm. It tingles and it is painful >2 months after receiving the shot.
This case was reported by a consumer and described the occurrence of sick in a 24-year-old female subject who was vaccinated with HAVRIX (GlaxoSmithKline). A physician or other health care professional has not verified this report. Concurrent medical conditions included allergy to avocado, allergy to onion and allergy to spinach. Previous and/or concurrent vaccination included TDap; manufacturer unspecified; unknown; unknown given in October 2008. The subject stated that she received other vaccines that same day, details not provided. There were no concurrent medications. On an unspecified date in October 2008 the subject received 1st dose of HAVRIX (unknown). On an unspecified date in October 2008, less than one day after vaccination with HAVRIX, the subject experienced diarrhea, vomiting, weakness and sick. The same evening as the vaccination and the next day, the subject reported diarrhea and vomiting; she also had weakness and was sick for approximately one week. At the time of reporting the diarrhea, vomiting, weakness and sick were resolved.
My injection site became itchy within 20 minutes after injection was given. At about 8pm that same night the injection site was red, raised, swollen, warm to touch and very painful. At this same time I developed a fever of 101.5. The rash became bigger and more swollen into Sunday (02/14/21). I also had fatigue, severe body aches, headache and jaw pain. The fever lasted 24 hours and subsided Saturday night at 8pm (02/13/21).  I felt ill into Tuesday (02/16/21).  As of now 2pm on 02/17/21 my only side effect left is the injection site is very itchy. The redness has gone away.
Fatigue, redness radiated over 4 day period from injection site and eventually covered most of upper arm, hard lump and bruise at injection site lasted 5 days, body aches, severe headache, nausea that would come and go, lethargy.
Mother described: Purple lips but breathing, Vomiting, Fever, Loss of Consciousness, No Jerking or twitching reported
Patient stated he felt light headed and dizzy with the first Pfizer vaccine and requested to lay down to have the Vaccine administered.  The nurse took the patient to a private area, with the mother and brother.  The nurse vaccinated the patient at 1423, patient then had a seizure at 1425, I was called to assisted.  Patient at the time was crying and felt sick.  I asked for the nurse to place the patient on his left side while I obtained the necessary equipment for vital signs.  Patient then became no verbal, I Immediatley asked for the staff to call 911.  Patient was cool, diaphoresis, not responding. I sternal rubbed the patient as he was not responding.  He was breathing, O2 saturation was 98%, HR 59. Vital signs 100/60 RR 16. Patient remained non-verbal.  I asked the mother if the patient had any medical conditions and she stateed no.  I asked about seizures and then the brother stated the patient had seizure when he was child about 3 years ago and the patient currently is not on any seizure medication. EMS was called at 1427 and are in route. Vital signs again, 110/78, HR 78, resp 18. I continued to ask the patients questions and the patient remained no-verbal.  The patient followed directions, but remained non verbal.  EMS arrived 1435 and took over.  Patient did awake a little more and stated he didnt want to go to the hospital.  EMS took the patient to the nearest Hospital
Severe headache; Muscle aches; Feeling of unwell; Fatigue; Chills; Hot flashes; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 79-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the arm left on 12Mar2021 at 10:00 (at the age of 79-years-old), as a single dose for COVID-19 immunisation. Medical history included chronic fatigue and grave's disease. The patient had unspecified allergy to medications, food, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Mar2021 at 10:15, the patient experienced severe headache, muscle aches, feeling of unwell, fatigue, chills, hot flashes and nausea. It was reported that, the headache was absolutely severe to the point that it was hard to keep eyes open and see. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for headache, muscle aches, feeling of unwell, fatigue, chills, hot flashes and nausea. The clinical outcome of events severe headache, muscle aches, feeling of unwell, fatigue, chills, hot flashes and nausea were resolved on an unknown date in Mar2021 (lasted 3 and half days).  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient had a syncope episode 10 min after he recieved covid 10 Jassen shot. Patient states that he Fell asleep and eventually Fell Off the chair . Patient sustained a ground level Fall. LOC lasted 10 Sec. Medical team identified Fall withing Few Seconds and came to Release. Patient fell on his abdomen and sustained mild temporal abrasion. He regained consciousness within 10 seconds and was Alert and oriented X4 (Place, time, Person). During Fall noted tense body with jerking movement for 5-7 seconds. Patient was informed that 911 call is being placed but patient refused and requested that his mom pick him up and take him to hospital if needed Patient admit smoking 2-3 Joints of marijuana today. Last meal at 930 AM and have not been drinking water. Mother arrive and will be taking patient to the hospital.
This spontaneous report as received from a physician refers to a patient of unknown age and gender. The patient's medical history and current conditions were not provided. On 22-OCT-2015, the patient was vaccinated with an improperly stored dose of VARIVAX (Merck) (dose, frequency and route were not reported) lot # reported as L0010144, expiration date 24-MAR-2017. No adverse effects have been reported. This is one of several reports received from the same reporter. Additional information has been requested.
Patient was given a COVID-19 vaccine not authorized for their age group. Patient was monitored for 15 minutes after the injection and no side effects were observed at that time. To this date, patient and/or guardian has not reported any side effects or symptoms since being vaccinated. Patient has since completed the vaccination series as recommended. A discussion occurred about how the error took place and strategies have been implemented to ensure that the error does not happen again.
Information has been received from a health professional concerning a 5 year old male pt who may have been vaccinated with a dose of varicella virus vaccine live. Subsequently, on approx 06Apr04, the pt developed breakthrough chickenpox with less than 50 lesions. Follow up information indicated that there was no a single report of adverse reaction following varicella vaccination. The reporter indicated that 49 other pt's developed breakthrough cases of chickenpox (WAES0404USA02615, WAES0405USA00572, WAES0405USA00573, WAES0405USA00574, WAES0405USA00575, WAES0405USA00580, WAES0405USA00581, WAES0405USA00582, WAES0405USA00583, WAES0405USA00584, WAES0405USA00585, WAES0405USA00586, WAES0405USA00588, WAES0405USA00589, WAES0405USA00590, WAES0405USA00591, WAES0405USA00592, WAES0405USA00593, WAES0405USA00594, WAES0405USA00595, WAES0405USA00596, WAES0405USA00597, WAES0405USA00598, WAES0405USA00599, WAES0405USA00600, WAES0405USA00601, WAES0405USA00602, WAES0405USA00603, WAES0405USA00604, WAES0405USA00605, WAES0405USA00606, WAES0405USA00607, WAES0405USA00608, WAES0405USA00609, WAES0405USA00610, WAES0405USA00611, WAES0405USA00612, WAES0405USA00613, WAES0405USA00614, WAES0405USA00615, WAES0405USA00616, WAES0405USA00617, WAES0405USA00618, WAES0405USA00619). No additional information is expected.
Severe gout in left feet and knee; This spontaneous case was reported by a consumer and describes the occurrence of GOUTY ARTHRITIS (Severe gout in left feet and knee) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced GOUTY ARTHRITIS (Severe gout in left feet and knee). The patient was treated with PREDNISONE at an unspecified dose and frequency and CAPSAICIN, MENTHOL, METHYL SALICYLATE (ULTRACIN) at an unspecified dose and frequency. At the time of the report, GOUTY ARTHRITIS (Severe gout in left feet and knee) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.
Patient had Rash and LUMP ON LEFT CLAVICAL AREA, She was diagnosed with LYMPHADENOPATHY. She noted the next morning of vaccine, had some burning sensation. She has to follow up the doctor in 3 to 4 days.
left arm swelling, redness, pain in Vaccine area patient received Covid vaccine on 04/09/21 1st dose
Extreme upper back pain (shoulder area) radiating to shoulder & neck. Bad headache, alternating between freezing to heavy perspiration. Unable to sleep. These symptoms continued for 3 days. Nausea the first 2 days. Back/ shoulder pain still.
Booster for Moderna accidentally given to a 16 year old. This was yet to be approved.
Received vaccine in p.m. On following a.m. parents state he was lethargic and weak. Unable to walk. Slight fever. In bed was emesis, stool and urine. On arrival to ER lethargic but soon became alert. Vomiting and loose stools since.
COVID 19; COVID 19; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP). The reporter is the patient.  A 38-year-old female patient (unknown if pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 18Nov2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 37 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid (Treatment start date: 07Jun2023, Treatment stop date: 11Jun2023).  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on available information, a possible contributory role of the sub product , BNT162B2 vaccine, cannot be excluded for suspected LOE.  There is limited information provided in this report. This case will be reassessed upon receipt of follow-up information.,Linked Report(s) : US-PFIZER INC-202300226209 same patients, different drugs and events;
Small red bumps, warm to touch, tender to touch, red streaks toward groin - beginning 12-17-10 A.M. lessened 12/18/10 but red streaks remain. OMNICEF oral suspension 125mg/5mL 1 tsp po BID x 5 days.